So, if the BP aren't interested in Her-Vaxx as they don't see any additional benefit to their current treatments then why wouldn't a smaller or medium size BP want this for $100M outright or exclusive license to penetrate the market where BP already has established themselves as a strategic solution to be direct competitor to them given Her-Vaxx has currently proven to be a better treatment????
IMU product line - HER-Vaxx, page-28
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.001(0.89%) |
Mkt cap ! $407.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.5¢ | $307.3K | 5.574M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 970785 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 668153 | 18 |
View Market Depth
| Last trade - 11.13am 25/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |